About us?

Pharmacielo-CES is an alliance between the CES and Pharmacielo to develop evidence-based research that allows the identification of short and long-term effects, beneficial or not, of the use of cannabis on health. Involve public and private entities, philanthropic organizations, that allow us to respond to missing key elements in cannabis research.

At a structured work level, the group will seek to ensure that there is sufficient and good quality data to inform the public about the effects (beneficial and harmful) of cannabis and by-products offered in the local market.
This work is done in conjunction with centers for the control and prevention of substances of abuse, the Ministry of Health, and entities in charge of the control of psychoactive substances, including the Attorney General's Office, the National Police, and the Ministry of Justice.

Pharmacielo-Ces works on two fronts that are: Pharmacology in which it seeks to promote the generation of knowledge in pharmaceutical sciences that develop new research options in the country that can solve health problems, related to Cannabic products both individually as a collective; and biotechnology that tries to develop important products at the agro-industrial level through the use of Molecular Biology as a biological tool to achieve this end.

Our results seek ...

• Evaluate the in vitro toxicity of compounds with bioactive potential.
• To evaluate the analgesic effect of cannabis and its components isolated by different routes in rheumatoid arthritis and to propose an MOA in-vitro.
• Evaluate the immunomodulatory effects of cannabis in different disease models.
• Determine the genetic variables of cannabis and its response to different treatments.
• Evaluate germplasm conservation techniques, mass propagation, cell cultures and molecular characterization of cannabis varieties.
• Study the effects of cannabiodes on neurocognition.
• Evaluate the use of cannabinoids in mental disorders (CBD in a subgroup of acute schizophrenic patients; THC in depression, anxiety, Post-Traumatic Stress, fragile X syndrome).
• Study the use of cannabinoids in dependence on alcohol, tobacco, heroin, benzodiazepines, and amphetamines.
• Evaluate the effect of abiotic factors on cannabinoid expression profiles in in vitro cell systems cultured in suspension.
• Adjust metabolic models that explain the expression profiles of metabolites of interest in cannabis (cannabinoids and terpenes).
• Evaluate the expression and purification of cannabinoid receptors for the study of various diseases.
• Study the interaction of cannabinoid receptors with isolated phytocannabinoids.